On Friday, Terry Fang, Director of the Genetic and Neurodevelopmental Disorders group at Biogen, gave the AGSAA an update on work they have done over the last few years to bring a potential new therapy to Aicardi-Goutieres Syndrome. The AGSAA’s research committee (Megan Veuleman, Juan Fran Navarro, Patrick Winters, and Devon Cordova) listened intently to some really compelling data and evidence. We’re all in agreement to bring this update to the community soon in the form of a webinar, and we’ll work to include an explanation from Biogen of why participation in the AGS Patient Registry will be critical to developing a successful clinical trial.